Pediatric Immunotherapy Discovery & Development Network (PI-DDN)

Implementation Team Co-Chairs: Judy Mietz, PhD and Nita Seibel, MD
Implementation Coordinator: Malcolm Smith, MD, PhD
Pediatric Immunotherapy Background

- The focus of adult immuno-oncology research is primarily on agents that boost the immune response to tumor neoantigens.

<table>
<thead>
<tr>
<th>Active Immuno-oncology Programs</th>
<th>Clinical Stage*</th>
<th>Preclinical/Discovery Stage</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD1</td>
<td>9</td>
<td>21</td>
<td>42</td>
</tr>
<tr>
<td>PDL1</td>
<td>7</td>
<td>22</td>
<td>28</td>
</tr>
<tr>
<td>CTLA4</td>
<td>5</td>
<td>15</td>
<td>27</td>
</tr>
<tr>
<td>IDO / TDO</td>
<td>2</td>
<td>12</td>
<td>17</td>
</tr>
<tr>
<td>TIM3</td>
<td>1</td>
<td>13</td>
<td>14</td>
</tr>
<tr>
<td>OX40</td>
<td>5</td>
<td>6</td>
<td>11</td>
</tr>
<tr>
<td>GITR</td>
<td>3</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>LAG3</td>
<td>3</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>CD137/4-1BB</td>
<td>2</td>
<td>3</td>
<td>5</td>
</tr>
</tbody>
</table>

* Inclusive of approved drugs.
Source: Thomson Cortellis pipeline database; Biomed Tracker; Atlas analysis.

These approaches may have limited applicability for childhood cancers.
Pediatric Immunotherapy Background

- The focus of adult immuno-oncology research is primarily on agents that boost the immune response to tumor neoantigens.
- Pediatric cancers generally have low mutation burdens and corresponding low rates of neoantigens resulting from somatic mutations.

![Childhood Cancers Diagram](Diagram.png)
Pediatric Immunotherapy Background

- Pediatric immunotherapy research is distinctive from adult immunotherapy research
- Pediatric cancers generally have low mutation burdens and corresponding low rates of neoantigens resulting from somatic mutations
- Focus of pediatric immunotherapy research on identifying and targeting:
  - Embryonal antigens with low expression in post-natal tissues
  - Antigens expressed on cells that are temporarily “expendable” (e.g., CD19, CD22)
- Primary therapeutic translation is engaging immune mechanisms to target non-mutated epitopes differentially expressed in pediatric cancers
Examples of Immuno-Oncology Agents for Children

- **Brentuximab vedotin**
  - Antibody-drug conjugate
  - Targeting CD30
  - Hodgkin lymphoma and anaplastic large cell lymphoma

- **Blinatumomab**
  - Bispecific T-cell Engaging antibody (BiTE)
  - Targeting CD19
  - Acute lymphoblastic leukemia (ALL)

- **CAR T-cells**
  - Targeting CD19 and CD22
  - Acute lymphoblastic leukemia (ALL)

**BUT**, resistance develops and need agents for pediatric solid tumors
Examples of Areas of Research Focus for the Pediatric Immunotherapy Discovery and Development Network

- Identification of antigenic epitopes that are uniquely and abundantly expressed on childhood and adolescent cancers.
- Development of optimized, highly specific binders for novel pediatric cancer immunotherapy targets.
- Development of candidate novel immunotherapy agents.
- Identification of cancer cell intrinsic and extrinsic mechanisms of immune evasion that limit the effectiveness of immunotherapy interventions against pediatric cancers.
- Development and application of approaches for in vivo preclinical testing of novel immunotherapy agents, including immune competent pediatric cancer models and humanized mouse models.
Pediatric Immunotherapy Discovery & Development Network

- A Collaborative Research Network with planned annual meetings to promote collaboration
- U54 multi-component programs to support collaborative investigator teams addressing two or more relevant synergistic areas of focus.
- U01 research projects to support discrete, individual or multi-PI projects addressing a relevant area of focus such as mechanisms of immune evasion, model development, validation of a single target, etc.
- NCI core services such as manufacturing and toxicology testing of agents developed by Network teams to support advancement to clinical testing in children.
- Funds set-aside for supplements for collaborations across the network for years 2-5.
Budget Considerations

- U54 multi-component programs (n = 1-2) at $4 million total costs per year for 5 years
- U01 research projects (n = 6-8) at an annual total cost of $4 million for all awards for 5 years
- Collaboration supplements for years 2-5 ($1 million total per year)
- Single receipt date in FY18 and FY19
NCI Cancer Immunotherapy Networks (Comprehensive)

- Pediatric Immunotherapy Discovery & Development Network (PI-DDN)
- Cancer Immunologic Data Commons (CIDC)
- Cancer Immunotherapy Translational Science Network (CI-TSN)
- Cancer Immune Monitoring and Analysis Centers (CIMACs)
- RFA-CA-17-006
- National Clinical Trials Network (NCTN)
- Cancer Immunotherapy Trials Network (CITN)
- Pediatric Early Phase Clinical Trials Network (PEP-CTN)
- Pediatric Brain Tumor Consortium (PBTC)
- Adult Brain Tumor Consortium (ABTC)
- Experimental Therapeutics Clinical Trials Network (ETCTN)
- RFA-CA-17-005
Markers of Success

- Discovery of new antigenic epitopes uniquely and abundantly expressed in pediatric cancers
- Development of highly specific binders for novel antigenic epitopes
- Development of novel immunotherapy agents
- Development of models for preclinical testing of immunotherapy agents
- Discovery of mechanisms of resistance
- Establishment of new collaborations for discovery and development of pediatric immunotherapy agents
- Entry of novel immunotherapy agents into pediatric clinical testing